Table 3.

Vision change before and after introduction of photodynamic and anti-VEGF therapies

	Decrease in vision, OR (95% CI)		Vision loss/blindness, OR (95% CI)
Covariate	Photodynamic therapy	Anti-VEGF therapy	Photodynamic therapy	Anti-VEGF therapy
Treatment	1.21**	0.59**	1.40**	0.54**
	(1.06,1.38)	(0.52,0.68)	(1.19,1.63)	(0.47,0.63)
Age	1.01	1.02**	1.02**	1.03**
	(0.99,1.02)	(1.01,1.03)	(1.01,1.03)	(1.01,1.04)
Male	0.83*	0.90	0.91	0.90
	(0.72,0.96)	(0.79,1.04)	(0.77,1.08)	(0.77,1.06)
Black	0.49*	0.70	0.47	0.62
	(0.25,0.96)	(0.39,1.25)	(0.21,1.05)	(0.31,1.26)
Hispanic	0.63	1.26	0.68	1.62
	(0.23,1.69)	(0.67,2.39)	(0.22,2.14)	(0.83,3.18)
Charlson Index	1.02	1.03	0.99	1.02
	(0.99,1.05)	(1.00,1.06)	(0.96,1.04)	(0.98,1.05)
Diabetes mellitus	1.02	0.87	0.90	0.83
	(0.85,1.22)	(0.74,1.03)	(0.72,1.13)	(0.68,1.01)
Glaucoma	1.13	1.01	1.28**	1.12
	(0.97,1.31)	(0.87,1.17)	(1.07,1.53)	(0.94,1.32)
Diabetic Retinopathy	0.84	1.09	1.24	1.24
	(0.59,1.2)	(0.81,1.47)	(0.84,1.83)	(0.89,1.74)
Cataract	1.18*	0.87*	1.10	0.87
	(1.02,1.37)	(0.76,0.99)	(0.93,1.31)	(0.75,1.02)
Other Eye Complication	1.46**	1.27**	1.42**	1.21*
	(1.25,1.69)	(1.09,1.48)	(1.19,1.70)	(1.01,1.45)
N	31,746	35,726	31,536	35,400
Percent with Outcome	2.95	2.62	2.97	2.64

Abbreviations: OR, odds ratio; CI, confidence interval

^**p<0.01,

^*p<0.05